Development of Osmotically Controlled Drug Delivery System: Development and In-vitro Evaluation of Elementary Osmotic Pump (Tablet) of Etoricoxib

Etoricoxib is non steroidal anti-inflammatory drug specifically Cyclooxygenase 2 (COX-2) enzyme inhibitor. Etoricoxib have serious side effect like gastric disturbance, gastric ulceration, gastrointestinal (GIT) bleeding. Conventional drug delivery systems do not have much control over the drug release and effective concentration of drug reach at the target site. It may lead to unsteady plasma drug level result into adverse effect due to plasma drug level crossing therapeutic window and undertherparutic response because of plasma drug level below therapeutic window. GIT side effect of Etoricoxib due to unsteady plasma drug level when administered in conventional dosage form. Development of elementary osmotic pump for etoricoxib release the drug in controlled fashion by zero order result in mentainance of constant plasma drug level for long period of time lead to diminished serious GIT side effect of etoricoxib.